News

Filter

Current filters:

UKGlaxoSmithKline

1 to 9 of 40 results

Milestone for GSK/NIH candidate Ebola vaccine as first doses shipped for Phase III trial

Milestone for GSK/NIH candidate Ebola vaccine as first doses shipped for Phase III trial

23-01-2015

UK pharma major GlaxoSmithKline said this morning that the first batch of its candidate Ebola vaccine…

EbolaGlaxoSmithKlinePharmaceuticalResearchUKVaccines

World’s largest collection of deprioritized pharma compounds opens to researchers

World’s largest collection of deprioritized pharma compounds opens to researchers

09-12-2014

A collection of 68 deprioritized pharmaceutical compounds is being made available to academic researchers…

AstraZenecaEli LillyGlaxoSmithKlineJanssen Research & DevelopmentPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

VIDEO: Chief executive Sir Andrew Witty discusses GSK's results

VIDEO: Chief executive Sir Andrew Witty discusses GSK's results

24-10-2014

Chief executive of UK pharma giant GlaxoSmithKline Sir Andrew Witty has commented on the company's third…

FinancialGlaxoSmithKlinePharmaceuticalPharmaceutical industryUK

GlaxoSmithKline’s third-qtr results not as bad as expected

GlaxoSmithKline’s third-qtr results not as bad as expected

22-10-2014

UK pharma giant GlaxoSmithKline has reported a downturn in both sales and profits for the third quarter…

FinancialGlaxoSmithKlinePharmaceuticalThomson ReutersUKViiV Healthcare

NICE recommends another new skin cancer drug, GSK’s Tafinlar

22-10-2014

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTafinlarUK

ESMO 2014: GSK reports 45% survival rate in Tafinlar trial

ESMO 2014: GSK reports 45% survival rate in Tafinlar trial

29-09-2014

UK pharma major GlaxoSmithKline presented data at the European Society for Medical Oncology’s congress…

DacarbazineGlaxoSmithKlineOncologyPharmaceuticalResearchTafinlarUK

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

GlaxoSmithKline confirms Sir Philip Hampton to be chairman

GlaxoSmithKline confirms Sir Philip Hampton to be chairman

25-09-2014

UK pharma giant GlaxoSmithKline this morning confirmed recent rumors, saying that Sir Philip Hampton…

BoardroomGlaxoSmithKlineManagementPharmaceuticalUKUnited Kingdom

1 to 9 of 40 results

COMPANY SPOTLIGHT

Menarini

Back to top